What is Journey Medical Corporation's (DERM) StockRank?

MoatMap's StockRank for Journey Medical Corporation (DERM) is 24/100, with a Sell signal. This is a composite score combining Quality (41), Value (22), and Momentum (48) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Journey Medical Corporation have an economic moat?

Journey Medical Corporation (DERM) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Journey Medical Corporation a buy, hold, or sell?

MoatMap's current signal for Journey Medical Corporation (DERM) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Journey Medical Corporation in?

Journey Medical Corporation (DERM) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DERM

SellSinker

Journey Medical Corporation · Healthcare · United States · $211M · Avg Vol: $1M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-23.8%

D/E

0.8x

Dividend %

—

COMPANY DESCRIPTION

Journey Medical Corporation is a pharmaceutical company focused on the acquisition, development, and commercialization of branded and generic dermatology products. The company aims to provide innovative solutions for various skin conditions, leveraging a focused sales force to target dermatologists and primary care physicians. Its strategy of acquiring established products and developing new formulations provides a niche within the competitive dermatology market.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	73.7M	79.2M	56.1M	61.9M	-5.7%	68.2M	81.4M	130.4M	45.2%
EPS	-1.69	-0.21	-0.72	-0.47	—	-0.22	—	—	—
Shares	17.8M	19.3M	22.2M	27.1M	+52.8%	22.2M	—	—	—
Debt	23.0M	14.7M	25.1M	25.4M	3.4%	25.5M	—	—	—
Equity	17.0M	20.4M	20.1M	31.9M	23.3%	—	—	—	—
Op CF	-13.5M	5.2M	-9.1M	-12.4M	—	-7.5M	—	—	—
Inv CF	-20.0M	-5.0M	-15.0M	0	—	—	—	—	—
Fin CF	16.5M	-4.8M	17.0M	16.2M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+21.1%

SMA 50SMA 200

$7.45

RSI (14)

61.5

52W High

$9.56

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-10.2%34.7

ROE

-23.8%28.8

GP/Assets

47.2%84.7

Op. Margin

2.5%47.0

FCF/Assets

-5.8%34.0

Piotroski

431.0

Int. Cover

-1.6x32.5

D/E Ratio

0.80x18.1

Current Ratio

1.59x28.8

Value

P/E (TTM)

—N/A

EV/EBITDA

182.4x2.8

P/FCF

—N/A

P/B

6.8x19.8

P/S

3.3x54.3

Div Yield

—N/A

Momentum

52W High %

78%63.9

RS 6M

-22%37.9

SMA 50/200

1.01x57.8

EPS Rev 4W

0.0%34.5

EPS Rev 12W

0.0%41.6

EPS Improve

+73%66.2

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$211M

P/E (Forward)

-131.0x

Gross Margin

65.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DERM are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DERM	Journey Medical Corporation(you)	$211M	24	Sell
ORGO	Organogenesis Holdings Inc.	$224M	29	Sell
SIGA	SIGA Technologies, Inc.	$220M	30	Sell
AKBA	Akebia Therapeutics, Inc.	$243M	17	Strong Sell
LFCR	Lifecore Biomedical, Inc.	$172M	16	Strong Sell
CPIX	Cumberland Pharmaceuticals Inc.	$127M	38	Hold
TLPH	Talphera, Inc.	$62M	24	Sell
CL.CN	Cresco Labs Inc.	$291M	43	Hold
VREO.CN	Vireo Growth Inc.	$552M	33	Sell
CWEB.TO	Charlotte's Web Holdings, Inc.	$80M	15	Strong Sell

Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%

Journey Medical Corporation (DERM): Stock Score Summary

Journey Medical Corporation (DERM) has a MoatMap StockRank of 24/100 based on Quality (41/100), Value (22/100), and Momentum (48/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$7.45
Market Cap	$211M
P/E (Forward)	-131.00
Price/Book	6.77
Return on Equity	-23.8%
Return on Invested Capital	-10.2%
Debt/Equity	0.80x
Gross Margin	65.5%
Operating Margin	2.5%
Revenue Growth	23.3%
Free Cash Flow	$-5M

Journey Medical Corporation operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Journey Medical Corporation’s (DERM) StockRank?: MoatMap’s StockRank for Journey Medical Corporation (DERM) is 24/100, with a Sell signal. It is a composite of Quality (41), Value (22), and Momentum (48) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Journey Medical Corporation have an economic moat?: Journey Medical Corporation (DERM) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Journey Medical Corporation a buy, hold, or sell?: MoatMap’s current signal for Journey Medical Corporation (DERM) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Journey Medical Corporation in?: Journey Medical Corporation (DERM) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).